论文部分内容阅读
肺动脉高压(PAH)是临床较为常见且治疗困难的肺心血管疾病,主要病理特征为肺血管收缩反应增强和肺动脉平滑肌细胞增生、肥厚导致的肺动脉血管重塑。传统治疗措施包括血管扩张剂疗法、抗凝剂及正在研究的一些抗增殖、促凋亡药物等疗效均有限,无法从根本上解决肺血管重塑的问题。而目前正在兴起的干细胞治疗技术有可能在PAH治疗中获得独特疗效,通过移植干细胞在肺内分化形成新生血管网替代病变肺动脉血管将可能达到彻底治愈的目的。现就此方面的研究和应用进展作一介绍。
Pulmonary hypertension (PAH) is a more common clinical and treatment of pulmonary heart disease, the main pathological features of pulmonary vasoconstriction and enhanced pulmonary vascular smooth muscle cell proliferation, hypertrophy caused by pulmonary vascular remodeling. Traditional therapies include vasodilator therapy, anticoagulants and some of the antiproliferative and proapoptotic drugs under study, which have limited efficacy and can not fundamentally solve the problem of pulmonary vascular remodeling. The emerging stem cell therapy technology may obtain unique therapeutic effects in the treatment of PAH. It is possible to achieve complete cure by transplanting stem cells to differentiate into diseased pulmonary arteries in the lung to form a neovascular network. Now on this aspect of research and application of an introduction.